

CADILA HEALTHCARE

PHARMACEUTICALS

18 AUG 2017

Quarterly Update

BUY

Target Price: Rs 540

Q1 miss; outlook strong – upgrade to BUY

Q1FY18 EBITDA margin declined 1,000 bps YoY/ 590 bps QoQ to 12.4% on negative operating leverage, as India sales declined 19% YoY. EBITDA margin adj. for GST stood at ~18%. US sales grew 3% QoQ in USD terms aided by full quarter consolidation of Sentyln. We expect its India business (post GST) growth to rebound to mid-teens and US business (post Moraiya clearance) to post 32% CAGR over FY17-19E, leading to 340 bps/580 bps EBITDA margin expansion to 23.6%/26% in FY18/19.

We largely maintain estimates, but upgrade to **BUY** with a revised TP of Rs 540 (22x FY19 EPS), as we believe it is best positioned (vs. peers) given strong earnings visibility led by monetization of its niche portfolio in India (biosimilar) and US (mesalamine franchise, transdermals).

CMP : Rs 483
Potential Upside : 12%

MARKET DATA

No. of Shares : 1,024 mn
Free Float : 25%
Market Cap : Rs 494 bn
52-week High / Low : Rs 558 / Rs 330
Avg. Daily vol. (6mth) : 1.4 mn shares
Bloomberg Code : CDH IB Equity
Promoters Holding : 75%
FII / DII : 10% / 7%

- ♦ **Q1 miss on weak India sales:** India formulations sales (29% of sales) declined 19% YoY on channel destocking due to GST rollout, while consumer wellness (5% of sales) declined marginally 1% YoY. US sales (45% of sales) grew 18% YoY/ 3% QoQ in USD terms aided by full quarter consolidation of Sentyln as well as launch of gTamiflu in Q4'17. Gross margin declined 347 bps YoY/ 15 bps QoQ to 60.3% (vs. estimate of 61.5%) led by lower India sales and lower margin AG[^] (Asacol HD) sales in US. EBITDA margin declined 1,000 bps YoY/ 590 bps QoQ to 12.4% led by negative operating leverage, as lower sales pushed employee and other operating costs as % to sales up. Cadila stated normalized EBITDA margin (adj. for GST) stood at ~18%. Reported EBITDA declined 47% YoY (~40% below estimates), while PAT declined 65% YoY (~55% below our estimate) on higher depreciation and interest cost
- ♦ **Monetization of niche pipeline from Moraiya has started** with launch of gLialda – sole generic, gRelpax – 2 generics, and approval for gAsacol HD (currently selling as AG[^]) which would kick start growth in the US. Additionally, approvals for niche generics gPrevacid Solutab (expected by Dec'17), gTamiflu OS#, gExelon transdermal patch are expected over next 9-12 months. We expect 32% CAGR in US business over FY17-19E

Financial summary (Consolidated)

Y/E March	FY16	FY17	FY18E	FY19E
Sales (Rs mn)	90,716	92,198	1,15,092	1,33,428
Adj PAT (Rs mn)	19,278	14,879	18,846	25,115
Con. EPS* (Rs)	-	-	19.6	24.3
EPS (Rs)	18.8	14.5	18.4	24.5
Change YOY (%)	66.6	(22.8)	26.7	33.3
P/E (x)	25.6	33.2	26.2	19.7
RoE (%)	38.7	23.5	28.9	35.4
RoCE (%)	28.1	16.3	20.7	26.8
EV/E (x)	21.8	27.8	19.2	14.7
DPS (Rs)	3.2	3.2	3.5	3.9


Source: *Consensus broker estimates, Company, Axis Capita

[^]AG = Authorized generic #OS- Oral suspension

Key drivers

Growth (%)	FY17	FY18E	FY19E
US	(10)	50	17
India	9	11	13
EBITDA margin (%)	20.3	23.6	26.0
EPS	(23)	27	33

Price performance



(...continued from page 1)

- ♦ **Operating leverage, increased capacity utilization to aid margin expansion:** We expect EBITDA margin to expand by ~340 bps to 23.6% in FY18E [vs. normalized EBITDA margin (adj. for GST) of 18% in Q1FY18, 20.2% in FY17] largely led by niche launches (gLiialda, gRelpax, etc.) in the US. We expect further margin improvement of 240 bps in FY19E to 26% led by launch of its own generic gAsacol HD – with significantly higher margin vs. ~18-20% margin from AG@ sales in FY18. CDH has already received 24 final approvals FY18 YTD across facilities with ~160 ANDA's still awaiting approval
- ♦ **Other concall highlights:** (1) **US:** Witnessed low to mid double digit YoY price erosion in Q1; **Launch momentum:** CDH launched 3-4 new products in Q1FY18 (received approval for 18 products in Q1FY18) with remaining products to be launched over next 2-3 quarters. **gLiialda:** Expects it has 180 day exclusivity (as FDA Formal letter has specified CDH is the first filer); does not expect authorized generic launch; (3) **R&D:** R&D spends increased 25% YoY (-7% QoQ) to Rs 2.04 bn (at 9.4% of Q1FY18 sales vs. 7.2% of Q1FY17 sales). Expects R&D to increase from Q2FY18, towards clinical trials for NCE, ANDA R&D. Filed 2 ANDA's in Q1FY18; (4) **India:** Expects mid teen growth for 9MFY18; expects higher growth in Q2; (5) **Tax rate:** Effective tax <20% for FY18; (6) **Capex:** FY18/19 capex of ~Rs 8-10 bn (excluding M&A) related to automation of facilities

Exhibit 1: Revenue decline led by GST impact on India business

(Rs mn)	% of Q1'18 sales	Q1'17	Q4'17	Q1'18	YoY (%)	QoQ (%)
Domestic	35%	9,023	9,602	7,520	(17)	(22)
Formulations	29%	7,862	8,402	6,374	(19)	(24)
Wellness	5%	1,161	1,200	1,146	(1)	(5)
Exports	63%	13,211	14,526	13,741	4	(5)
Formulations	55%	11,138	12,518	11,995	8	(4)
US (USD mn)		127	146	150	18	3
US	45%	8,483	9,851	9,650	14	(2)
Europe	3%	792	620	608	(23)	(2)
Latam	2%	527	603	509	(3)	(16)
Other Emerging Markets	6%	1,336	1,444	1,228	(8)	(15)
APIs	3%	976	934	689	(29)	(26)
Animal Health & Others	5%	1,097	1,074	1,057	(4)	(2)
Alliances	2%	390	514	411	5	(20)
Total		22,624	24,642	21,672	(4)	(12)

Source: Axis Capital, Company

Exhibit 2: Other operating income declined YoY

(Rs mn)	Q1'17	Q4'17	Q1'18	YoY	QoQ
Other operating income	707	608	616	(13)	1
- Export Incentive	287	214	272	(5)	27
- Royalty Income	30	2	5	(83)	150
- Net gain on foreign currency transactions	231	(81)	-	(100)	(100)
- Others	159	474	338	113	(29)

Source: Company

Exhibit 3: Lower India sales led to negative operating leverage

(Rs mn)	Q1'17	Q4'17	Q1'18	YoY (%)	QoQ (%)
Revenues	22,624	24,642	21,672	(4)	(12)
Other operating Income	707	607	616	(13)	1
Total revenues	23,331	25,249	22,288	(4)	(12)
Gross margin (%)	63.8	60.4	60.3	-347 bps	-15 bps
Employees cost	3,572	4,005	4,288	20	7
% to sales	15.8	16.3	19.8	400 bps	353 bps
R&D Expenses	1,626	2,180	2,038	25	(7)
% to sales	7.2	8.8	9.4	222 bps	56 bps
Other Expenditure	4,693	4,677	4,580	(2)	(2)
% of sales	20.7	19.0	21.1	39 bps	215 bps
EBITDA	5,239	4,636	2,773	(47)	(40)
EBITDA margin (%)	22.5	18.4	12.4	-1001 bps	-592 bps
Adjusted EBITDA*	4,771	4,981	2,790	(42)	(44)
Adjusted EBITDA margins	20.4	19.7	12.5	-793 bps	-721 bps
Depreciation	843	1,145	1,220	45	7
Other Income	153	731	210	37	(71)
Financial cost	140	99	219	56	121
Profit before tax	4,409	4,123	1,544	(65)	(63)
Effective tax rate	12.3	0.5	19.0	664 bps	1852 bps
Reported PAT	3,984	3,855	1,384	(65)	(64)

Source: Company, as per Ind-AS *margin adjusted for forex

Conference call highlights and our view
Guidance

- ♦ **India:** Expect mid-high teen growth in Q2FY18
- ♦ **R&D:** 8% of sales in FY18
- ♦ **Capex:** FY18/19 capex of ~Rs 8-10 bn (excluding M&A) related to automation of facilities
- ♦ **Tax rate:** Current tax of 12-15% in FY18. Effective tax <20% for FY18
- ♦ **M&A:** Looking at specialty molecules targeting Pain, Derma, Oncology, GI therapeutic areas in the US, (~USD 100 mn). Also looking at acquiring platforms to expand geographical footprint

US business (USD 150 mn, +18% YoY/ +3% QoQ)

- ♦ **Base business** witnessed low to mid double digit YoY price erosion in Q1. US base business (ex Sentyln) was largely flat YoY, as pricing erosion was offset by market share gains
- ♦ Received approval for 18 products in Q1FY18. CDH launched 3-4 new products in the quarter, with remaining products to be launched over next 2-3 quarters. It will not be launching ~20% of products due to commercial unviability – development expenses for the same, have been expensed in the P&L
- ♦ **gLiialda:** Does not expect authorized generic launch. Expects it has 180 day exclusivity (as FDA Formal letter has specified CDH is the First filer). Formal exclusivity not assigned, as no other filer is currently in the final stages of receiving approval
- ♦ **Metoprolol XL:** TAD in Mar' 2018
- ♦ **Prevacid Solutab:** Expects approval in CY17
- ♦ **gTamiflu (oral Suspension):** Expect approval in FY18; only 2 filers
- ♦ **gRenvela:** Has an API source problem. Looking for secondary source
- ♦ **Transdermal:** Expects approval for couple of products in FY18
 - **gExelon:** Answered all queries, expects approval in FY18

Domestic formulations (Rs 6,374 mn; -19% YoY)

- ♦ Impacted by trade channel destocking ahead of GST rollout. Did not offer longer credit terms in Q1FY18
- ♦ Expects partial channel restocking in Q2FY18. Witnessed healthy sales in Q2FY18

LatAm (Rs 509 mn; -3% YoY)

- ♦ Received approval for 1 product from Anvisa (Brazil), and launched 1 product in Brazil

R&D

- ♦ R&D spends increased 25% YoY (-7% QoQ) to Rs 2.04 bn (at 9.4% of Q1FY18 sales vs. 7.2% of Q1FY17 sales). Filed 2 ANDA's in Q1FY18
- ♦ Expects R&D to increase from Q2FY18 towards clinical trials for NCE, ANDA R&D


Vaccines

- ♦ Received approval to initiate phase 3 trials for 2 vaccines
- ♦ Initiated phase 2 trials for 1 vaccine
- ♦ To target WHO tenders, Unicef tenders over the next 3 years. All developmental expenses towards vaccines being expensed in P&L

Financials


- ♦ Normalized EBITDA margin (adjusted for GST) stood at ~18% in Q1FY18 (vs. reported margin of 12.5%)
- ♦ Steady gross margin in Q1FY18 due to consolidation of Sentyln Therapeutics despite lower India sales
- ♦ No plans to raise funds in the near term

Exhibit 4: Higher R&D expense in Q1'18



Source: Company

Exhibit 5: Significant pickup in approvals in Q1'18




Source: Company


Exhibit 6: Ramp-up in Asacol HD (AG) share continues; HCQS market share steady

Launched	Brand	Brand/Mkt size (USD mn)	No. of generics	Market Share %						
				Jun'16	Sep'16	Dec'16	Mar'17	Apr'17	May'17	Jun'17
2QFY14	Wellbutrin XL	792	5	4	6	<1	<1	<1	<1	<1
2QFY17	Asacol HD (AG)	250	1	-	37	49	58	59	61	62
4QFY14	Tricor (AG)	1,300	7	18	18	18	17	11	7	6
4QFY14	Trilipix (AG)	450	5	23	23	24	23	23	23	23
1QFY15	Zemplar (AG)	109	8	54	64	70	66	65	65	62
2QFY15	Niaspan (AG)	1,000	5	10	8	7	4	3	3	2
Sep '14	Urocit - K	130	2	45	45	46	52	54	55	55
NA	HCQS	100	7	35	30	30	28	30	29	29
3QFY16	Benzonatate	40	9	13	13	14	14	13	14	14

Source: Bloomberg

Exhibit 7: IPM: Lower volume uptake impacted Q1'18 growth


Source: AIOCD, IPM = India Pharma market

Exhibit 8: CDH: Sharp uptick in volumes in recent quarters


Source: AIOCD

Exhibit 9: Sharp uptick in volumes led by improvement in anti-infectives, Pain, anti-Neoplastics segments

YoY growth	% sales	FY16	FY17	Q1'17	Q4'17	Q1'18	Apr'17	May'17	Jun'17
Cardiac	15	12	7	(0)	7	6	7	1	12
Gastro Intestinal	12	10	11	9	12	4	4	2	5
Anti-Infectives	15	19	16	5	6	25	11	35	30
Gynaecological	10	10	(3)	(13)	5	8	6	8	10
Respiratory	10	18	14	3	10	10	13	8	8
Pain / Analgesics	9	13	16	11	14	29	20	31	36
Derma	7	11	13	8	17	(4)	(1)	(7)	(3)
Anti-Neoplastics	6	10	47	5	76	25	(11)	47	39
Vit. / Min / Nut	4	13	23	12	29	22	19	24	23
Anti Malarials	1	14	(26)	(29)	(41)	(5)	(17)	1	(2)
Total (Rs bn)	47	12	12	2	14	18	8	16	19

Source: AIOCD *% of FY17 sales

Financial summary (Consolidated)

Profit & loss (Rs mn)

Y/E March	FY16	FY17	FY18E	FY19E
Net sales	90,716	92,198	1,15,092	1,33,428
Other operating income	3,551	2,097	2,250	2,500
Total operating income	94,267	94,295	1,17,342	1,35,928
Cost of goods sold	(30,959)	(34,451)	(41,607)	(45,585)
Gross profit	63,308	59,844	75,735	90,342
<i>Gross margin (%)</i>	<i>69.8</i>	<i>64.9</i>	<i>65.8</i>	<i>67.7</i>
Total operating expenses	(40,004)	(40,808)	(48,053)	(55,029)
EBITDA	23,304	19,036	27,683	35,313
<i>EBITDA margin (%)</i>	<i>25.7</i>	<i>20.6</i>	<i>24.1</i>	<i>26.5</i>
Depreciation	(3,001)	(3,750)	(4,779)	(5,191)
EBIT	20,303	15,286	22,903	30,123
Net interest	(528)	(450)	(949)	(869)
Other income	1,156	1,286	950	1,250
Profit before tax	20,926	16,121	22,904	30,504
Total taxation	(1,774)	(1,289)	(4,008)	(5,338)
<i>Tax rate (%)</i>	<i>8.5</i>	<i>8.0</i>	<i>17.5</i>	<i>17.5</i>
Profit after tax	19,152	14,832	18,896	25,165
Minorities	(304)	(291)	(450)	(450)
Profit/ Loss associate co(s)	430	338	400	400
Adjusted net profit	19,278	14,879	18,846	25,115
<i>Adj. PAT margin (%)</i>	<i>21.3</i>	<i>16.1</i>	<i>16.4</i>	<i>18.8</i>
Net non-recurring items	(20)	(2)	-	-
Reported net profit	19,258	14,877	18,846	25,115

Balance sheet (Rs mn)

Y/E March	FY16	FY17	FY18E	FY19E
Paid-up capital	1,024	1,024	1,024	1,024
Reserves & surplus	55,968	68,576	59,689	80,034
Net worth	56,992	69,600	60,713	81,058
Borrowing	21,073	49,453	45,453	41,453
Other non-current liabilities	2,009	1,164	1,164	1,164
Total liabilities	81,432	1,21,778	1,08,891	1,25,236
Gross fixed assets	57,673	81,029	91,029	1,01,029
Less: Depreciation	(20,194)	(23,478)	(28,257)	(33,448)
Net fixed assets	37,479	57,551	62,772	67,581
Add: Capital WIP	9,508	15,433	15,433	15,433
Total fixed assets	46,987	72,984	78,205	83,014
Total Investment	2,487	1,134	1,134	1,134
Inventory	13,371	18,037	19,550	22,664
Debtors	17,466	22,775	20,496	23,761
Cash & bank	6,387	15,435	9,372	17,693
Loans & advances	18,808	21,842	6,306	7,311
Current liabilities	24,074	30,429	26,172	30,341
Net current assets	31,958	47,660	29,553	41,088
Other non-current assets	-	-	-	-
Total assets	81,432	1,21,778	1,08,891	1,25,236

Source: Company, Axis Capital

Cash flow (Rs mn)

Y/E March	FY16	FY17	FY18E	FY19E
Profit before tax	20,926	16,121	22,904	30,504
Depreciation & Amortisation	3,001	3,750	4,779	5,191
<i>Chg in working capital</i>	<i>2,717</i>	<i>(3,728)</i>	<i>12,044</i>	<i>(3,215)</i>
Cash flow from operations	18,935	13,495	35,719	26,760
<i>Capital expenditure</i>	<i>(9,571)</i>	<i>(29,734)</i>	<i>(10,000)</i>	<i>(10,000)</i>
Cash flow from investing	(8,635)	(29,103)	(10,000)	(10,000)
<i>Equity raised/ (repaid)</i>	<i>-</i>	<i>-</i>	<i>-</i>	<i>-</i>
<i>Debt raised/ (repaid)</i>	<i>(2,367)</i>	<i>14,992</i>	<i>(4,000)</i>	<i>(4,000)</i>
<i>Dividend paid</i>	<i>(6,891)</i>	<i>(3,938)</i>	<i>(4,337)</i>	<i>(4,771)</i>
Cash flow from financing	(9,700)	10,498	(9,287)	(10,021)
Net chg in cash	600	(5,110)	16,432	6,739

Key ratios

Y/E March	FY16	FY17	FY18E	FY19E
OPERATIONAL				
FDEPS (Rs)	18.8	14.5	18.4	24.5
CEPS (Rs)	21.7	18.2	23.1	29.6
DPS (Rs)	3.2	3.2	3.5	3.9
Dividend payout ratio (%)	17.0	22.0	19.1	15.8
GROWTH				
Net sales (%)	6.8	1.6	24.8	15.9
EBITDA (%)	32.7	(18.3)	45.4	27.6
Adj net profit (%)	66.6	(22.8)	26.7	33.3
FDEPS (%)	66.6	(22.8)	26.7	33.3
PERFORMANCE				
RoE (%)	38.7	23.5	28.9	35.4
RoCE (%)	28.1	16.3	20.7	26.8
EFFICIENCY				
Asset turnover (x)	1.4	1.1	1.1	1.3
Sales/ total assets (x)	0.9	0.7	0.8	0.9
Working capital/ sales (x)	0.3	0.3	0.2	0.2
Receivable days	70.3	90.2	65.0	65.0
Inventory days	68.8	87.5	79.6	82.2
Payable days	67.3	81.2	77.0	79.6
FINANCIAL STABILITY				
Total debt/ equity (x)	0.4	0.8	0.7	0.6
Net debt/ equity (x)	0.2	0.5	0.5	0.3
Current ratio (x)	2.3	2.6	2.1	2.4
Interest cover (x)	38.5	34.0	24.1	34.7
VALUATION				
PE (x)	25.6	33.2	26.2	19.7
EV/ EBITDA (x)	21.8	27.8	19.2	14.7
EV/ Net sales (x)	5.6	5.7	4.6	3.9
PB (x)	8.7	7.1	8.1	6.1
Dividend yield (%)	0.7	0.7	0.7	0.8
Free cash flow yield (%)	-	-	0.1	-

Source: Company, Axis Capital

Disclosures:

The following Disclosures are being made in compliance with the SEBI Research Analyst Regulations 2014 (herein after referred to as the Regulations).

1. Axis Securities Ltd. (ASL) is a SEBI Registered Research Analyst having registration no. INH000000297. ASL, the Research Entity (RE) as defined in the Regulations, is engaged in the business of providing Stock broking services, Depository participant services & distribution of various financial products. ASL is a subsidiary company of Axis Bank Ltd. Axis Bank Ltd. is a listed public company and one of India's largest private sector bank and has its various subsidiaries engaged in businesses of Asset management, NBFC, Merchant Banking, Trusteeship, Venture Capital, Stock Broking, the details in respect of which are available on www.axisbank.com.
2. ASL is registered with the Securities & Exchange Board of India (SEBI) for its stock broking & Depository participant business activities and with the Association of Mutual Funds of India (AMFI) for distribution of financial products and also registered with IRDA as a corporate agent for insurance business activity.
3. ASL has no material adverse disciplinary history as on the date of publication of this report.
4. I/We, authors (Research team) and the name/s subscribed to this report, hereby certify that all of the views expressed in this research report accurately reflect my/our views about the subject issuer(s) or securities. I/We also certify that no part of my/our compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this report. I/we or my/our relative or ASL does not have any financial interest in the subject company. Also I/we or my/our relative or ASL or its Associates may have beneficial ownership of 1% or more in the subject company at the end of the month immediately preceding the date of publication of the Research Report. Since associates of ASL are engaged in various financial service businesses, they might have financial interests or beneficial ownership in various companies including the subject company/companies mentioned in this report. I/we or my/our relative or ASL or its associates do not have any material conflict of interest. I/we have not served as director, officer or employee in the subject company.

Research Team

Sr. No	Name	Designation	E-mail
1	Hiren Trivedi	Research Associate	hiren.trivedi@axissecurities.in
2	Kiran Gawle	Associate	kiran.gawle@axissecurities.in

5. ASL or its associates has not received any compensation from the subject company in the past twelve months. ASL or its Research Analysts has not been engaged in market making activity for the subject company.

6. In the last 12-month period ending on the last day of the month immediately preceding the date of publication of this research report, ASL or any of its associates may have:

- Received compensation for investment banking, merchant banking or stock broking services or for any other services from the subject company of this research report and / or;
- Managed or co-managed public offering of the securities from the subject company of this research report and / or;
- Received compensation for products or services other than investment banking, merchant banking or stock broking services from the subject company of this research report;

ASL or any of its associates have not received compensation or other benefits from the subject company of this research report or any other third-party in connection with this report

Term& Conditions:

This report has been prepared by ASL and is meant for sole use by the recipient and not for circulation. The report and information contained herein is strictly confidential and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of ASL. The report is based on the facts, figures and information that are considered true, correct, reliable and accurate. The intent of this report is not recommendatory in nature. The information is obtained from publicly available media or other sources believed to be reliable. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. All such information and opinions are subject to change without notice. The report is prepared solely for informational purpose and does not constitute an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments for the clients. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. ASL will not treat recipients as customers by virtue of their receiving this report.

DEFINITION OF RATINGS	
Ratings	Expected absolute returns over 12-18 months
BUY	More than 10%
HOLD	Between 10% and -10%
SELL	Less than -10%

Disclaimer:

Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to the recipient's specific circumstances. The securities and strategies discussed and opinions expressed, if any, in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient.

This report may not be taken in substitution for the exercise of independent judgment by any recipient. Each recipient of this report should make such investigations as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this report (including the merits and risks involved), and should consult its own advisors to determine the merits and risks of such an investment. Certain transactions, including those involving futures, options and other derivatives as well as non-investment grade securities involve substantial risk and are not suitable for all investors. ASL, its directors, analysts or employees do not take any responsibility, financial or otherwise, of the losses or the damages sustained due to the investments made or any action taken on basis of this report, including but not restricted to, fluctuation in the prices of shares and bonds, changes in the currency rates, diminution in the NAVs, reduction in the dividend or income, etc. Past performance is not necessarily a guide to future performance. Investors are advised necessarily a guide to future performance. Investors are advised to see Risk Disclosure Document to understand the risks associated before investing in the securities markets. Actual results may differ materially from those set forth in projections. Forward-looking statements are not predictions and may be subject to change without notice.

ASL and its affiliated companies, their directors and employees may; (a) from time to time, have long or short position(s) in, and buy or sell the securities of the company(ies) mentioned herein or (b) be engaged in any other transaction involving such securities or earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or investment banker, lender/borrower to such company(ies) or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions. Each of these entities functions as a separate, distinct and independent of each other. The recipient should take this into account before interpreting this document.

ASL and / or its affiliates do and seek to do business including investment banking with companies covered in its research reports. As a result, the recipients of this report should be aware that ASL may have a potential conflict of interest that may affect the objectivity of this report. Compensation of Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions. ASL may have issued other reports that are inconsistent with and reach different conclusion from the information presented in this report.

Neither this report nor any copy of it may be taken or transmitted into the United State (to U.S. Persons), Canada, or Japan or distributed, directly or indirectly, in the United States or Canada or distributed or redistributed in Japan or to any resident thereof. If this report is inadvertently sent or has reached any individual in such country, especially, USA, the same may be ignored and brought to the attention of the sender. This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject ASL to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors.

The Disclosures of Interest Statement incorporated in this document is provided solely to enhance the transparency and should not be treated as endorsement of the views expressed in the report. The Company reserves the right to make modifications and alternations to this document as may be required from time to time without any prior notice. The views expressed are those of the analyst(s) and the Company may or may not subscribe to all the views expressed therein.

Copyright in this document vests with Axis Securities Limited.

Axis Securities Limited, Corporate office: Unit No. 2, Phoenix Market City, 15, LBS Road, Near Kamani Junction, Kurla (west), Mumbai-400070, Tel No. – 18002100808/022-61480808, Regd. off.- Axis House, 8th Floor, Wadia International Centre, PandurangBudhkarMarg, Worli, Mumbai – 400 025. Compliance Officer: AnandShaha, Email: compliance.officer@axisdirect.in, Tel No: 022-42671582.